Biotech Values

[lgonber]

Thanks for your reply. I understand your concers, and obviously is a clinical trial and until data is unblinded, we dont know what would happen. Nevertheless I am quite positive in the future outcome and my gut feeling, says they will hit primary endpoint. By the way I read you have referred to an old article to discuss about the vector, published in 2008. Bear in mind CLDN uses AAV1, which is different to AAV2, it is not the same.